RecruitingPhase 2Phase 3NCT05595447

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Rescue With Brentuximab Plus PD-1 Blockade Followed by Autotransplantation and Consolidation With Brentuximab Plus PD-1 Blockade in Patients With Relapsed/Refractory Hodgkin Lymphoma: Exploratory Single-arm Analysis

Sponsor

Hospital Regional de Alta Especialidad del Bajio

Enrollment

20 participants

Start Date

Oct 18, 2022

Study Type

INTERVENTIONAL

Conditions

Hodgkin Lymphoma Refractory Hodgkin Lymphoma Relapsed Hodgkin's Disease, Adult

Summary

The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT. What is the progression-free survival and rate of metabolic responses complete in patients with high-risk R/R HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade 1?

Eligibility

Min Age: 15 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study is examining treatment strategies for people with relapsed or refractory Hodgkin lymphoma that is considered high-risk after failing standard ABVD chemotherapy. The goal is to find better ways to manage this challenging situation. **You may be eligible if...** - You are 18–90 years old - You have Hodgkin lymphoma that has come back or not responded to ABVD chemotherapy and meets high-risk criteria - Your liver and kidney function are within acceptable limits - Your overall health allows for treatment participation (ECOG performance status 3 or better) **You may NOT be eligible if...** - You voluntarily withdraw from the study - You experience severe (grade 3–4) treatment-related side effects - You are lost to follow-up Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.